The company’s report states that although FNA is still the most popular biopsy method, growth will be slow as doctors are gradually shifting towards Core Needle Biopsy (CNB).
The Fine Needle Aspiration (FNA) segment of the biopsy market is set to remain relatively stagnant over the next few years, rising only slightly from $56 million in 2015 to $59.2 million in 2022, at a Compound Annual Growth Rate (CAGR) of 0.81%, according to research and consulting firm GlobalData.
The company’s report states that although FNA is still the most popular biopsy method–and used in the highest number of indications consisting of prostate cancer, liver cancer and thyroid cancer–growth will be slow, as doctors are gradually shifting towards Core Needle Biopsy (CNB).
Other market segments that will see much higher growth rates than FNA include vacuum-assisted biopsy, biopsy guns and biopsy forceps and punches, which will experience CAGRs of 3.97%, 3.70% and 1.63% respectively. Like CNB, these techniques have higher levels of accuracy than FNA, and they are more likely to be reimbursed.
GlobalData
www.globaldata.com
